Healthcare News

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today...

DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery  Positive outcomes from trial can potentially impact Veteran Affairs/Department of War...

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that it will present an invited...

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...

TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. company (Nasdaq: TLRY; TSX: TLRY) a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis...

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85:...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306...

Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement,...